Undisclosed anti-CLEC2D-TLR9 agonist conjugate / Immunitas Therap - LARVOL DELTA

Immunitas Therapeutics Presents New Data for TLR9 Agonist Conjugate at the Society for Immunotherapy of Cancer 2023 Annual Meeting (PRNewswire) - "Immunitas Therapeutics...presented the first proof-of-concept data on its second program, a myeloid and B cell modulating anti CLEC2D-Toll-like receptor 9 (TLR9) agonist conjugate, at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023)....The presented data showed that treatment with Immunitas' anti CLEC2D-TLR9 agonist immune stimulating antibody complex (ISAC) induced pro-inflammatory responses in THP1-TLR9 reporter cell lines and dramatically increased production of IFN-α, a critical cytokine for induction of anti-tumor T cells, in human plasmacytoid dendritic cells."

Preclinical • Oncology

Immunitas Therapeutics Presents Data for Novel Anti CLEC2D-TLR9 Conjugate Program at the Society for Immunotherapy of Cancer 2023 Annual Meeting (PRNewswire) - "Immunitas Therapeutics...announced it will present the first proof-of-concept data on its second program, a myeloid and B cell modulating anti CLEC2D-Toll-like receptor 9 (TLR9) agonist conjugate, at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023), held November 1-5....In vitro proof-of-concept for novel myeloid and B cell modulating anti-CLEC2D-TLR9 agonist conjugate program, a compelling immunotherapeutic approach to induce T and NK cell recruitment in tumors with otherwise low immunological activity."

Preclinical • Oncology